CA2909091C - Tumor-selective combination therapy - Google Patents

Tumor-selective combination therapy Download PDF

Info

Publication number
CA2909091C
CA2909091C CA2909091A CA2909091A CA2909091C CA 2909091 C CA2909091 C CA 2909091C CA 2909091 A CA2909091 A CA 2909091A CA 2909091 A CA2909091 A CA 2909091A CA 2909091 C CA2909091 C CA 2909091C
Authority
CA
Canada
Prior art keywords
dnq
cells
parp1
lap
cancer cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2909091A
Other languages
English (en)
French (fr)
Other versions
CA2909091A1 (en
Inventor
Paul J. Hergenrother
David A. Boothman
Joseph S. BAIR
Lifen CAO
Jimming GAO
Xiumei HUANG
Xiuquan LUO
Xinpeng MA
Zachary R. MOORE
Elizabeth I. PARKINSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Illinois System
Original Assignee
University of Texas System
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Illinois System filed Critical University of Texas System
Publication of CA2909091A1 publication Critical patent/CA2909091A1/en
Application granted granted Critical
Publication of CA2909091C publication Critical patent/CA2909091C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2909091A 2013-04-09 2014-04-08 Tumor-selective combination therapy Active CA2909091C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361810008P 2013-04-09 2013-04-09
US61/810,008 2013-04-09
PCT/US2014/033400 WO2014168991A1 (en) 2013-04-09 2014-04-08 Tumor-selective combination therapy

Publications (2)

Publication Number Publication Date
CA2909091A1 CA2909091A1 (en) 2014-10-16
CA2909091C true CA2909091C (en) 2021-11-02

Family

ID=51689971

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2909091A Active CA2909091C (en) 2013-04-09 2014-04-08 Tumor-selective combination therapy

Country Status (15)

Country Link
US (2) US10272099B2 (pl)
EP (1) EP2984184B1 (pl)
JP (2) JP6615746B2 (pl)
CN (2) CN111481551B (pl)
AU (2) AU2014251043B2 (pl)
BR (1) BR112015025662A2 (pl)
CA (1) CA2909091C (pl)
DK (1) DK2984184T3 (pl)
ES (1) ES2853973T3 (pl)
HU (1) HUE052930T2 (pl)
MX (2) MX2015014282A (pl)
PL (1) PL2984184T3 (pl)
PT (1) PT2984184T (pl)
WO (1) WO2014168991A1 (pl)
ZA (1) ZA201507755B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111481551B (zh) * 2013-04-09 2023-06-09 伊利诺伊大学董事会 肿瘤选择性联合疗法
WO2018005279A1 (en) * 2016-06-27 2018-01-04 Systems Oncology, Llc Combination chemotherapies
WO2019113345A1 (en) * 2017-12-06 2019-06-13 Spyro Mousses Combination of cancer therapeutics for treatment of cancer and hyperproliferative diseases
WO2019156684A1 (en) * 2018-02-12 2019-08-15 Solugen, Inc. Hydrogen peroxide production method, system, and apparatus
CN111936143A (zh) 2018-04-05 2020-11-13 诺维嘉研究公司 用于治疗癌症的微管蛋白聚合抑制剂和聚(adp-核糖)聚合酶(parp)抑制剂的新型联用药品
KR102875039B1 (ko) 2018-04-09 2025-10-22 영진약품 주식회사 1,2-나프토퀴논 유도체 화합물을 포함하는 고형암 또는 혈액암의 예방 또는 치료용 약학 조성물
MX2021011301A (es) * 2019-03-18 2022-01-19 Univ Texas Terapia combinada especifica contra tumores.
US20240197709A1 (en) * 2022-12-20 2024-06-20 The Trustees Of Indiana University Potentiating the tumor-selective effects of nqo1-bioactivatable agent by use of cmet inhibitor
WO2025047770A1 (ja) * 2023-08-31 2025-03-06 東レ株式会社 デオキシニボキノン誘導体の製造方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4906562A (en) * 1984-12-21 1990-03-06 Oncogen Monocolonal antibodies and antigen for human non-small cell lung carcinomas
ES2088822B1 (es) * 1994-02-24 1997-08-01 Univ Madrid Complutense Nuevos derivados antraquinonicos con actividad antitumoral y sus aplicaciones.
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6635677B2 (en) * 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
FR2797446B1 (fr) * 1999-08-13 2001-11-02 Lafon Labor Derives de phenanthroline-7-ones et leurs applications en therapeutique
CA2456985A1 (en) * 2001-08-15 2003-02-27 Icos Corporation 2h-phthalazin-1-ones and methods for use thereof
WO2003088954A1 (en) * 2002-04-15 2003-10-30 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
US6890950B2 (en) 2002-04-23 2005-05-10 Case Western Reserve University Lapachone delivery systems, compositions and uses related thereto
JP2006522088A (ja) * 2003-03-31 2006-09-28 ファイザー・インク ポリ（ａｄｐ−リボース）ポリメラーゼの三環系阻害剤の塩
US8614228B2 (en) * 2004-08-11 2013-12-24 Arqule, Inc. Quinone prodrug compositions and methods of use
WO2006024545A1 (en) * 2004-09-03 2006-03-09 Stichting Voor De Technische Wetenschappen Fused bicyclic natural compounds and their use as inhibitors of parp and parp-mediated inflammatory processes
EP1986640A1 (en) * 2006-02-09 2008-11-05 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment by using e09 and propylene glycol
JP5249239B2 (ja) * 2006-12-29 2013-07-31 トラコン ファーマシューティカルズ，インク． 癌の治療における葉酸代謝拮抗剤の併用
JP2011503111A (ja) 2007-11-12 2011-01-27 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる乳がんの治療
US20090275608A1 (en) 2008-02-04 2009-11-05 Bipar Sciences, Inc. Methods of diagnosing and treating parp-mediated diseases
BR112012021806A2 (pt) * 2010-03-01 2015-09-08 Myrexis Inc compostos e seus usos terapêusticos.
ES2602475T3 (es) 2010-04-15 2017-02-21 Tracon Pharmaceuticals, Inc. Potenciación de la actividad anticáncer por terapia de combinación con inhibidores de la vía BER
US9081428B2 (en) * 2010-04-23 2015-07-14 Psion Inc. Apparatus and method for impact resistant touchscreen display module
EA201390370A1 (ru) * 2010-09-15 2013-07-30 Олмак Дайэгностикс Лимитед Молекулярно-диагностический тест для определения онкологического заболевания
PT2619331T (pt) 2010-09-22 2018-06-01 Univ Texas Métodos de tratamento de cancro incluindo rastreio de nqo1
US20120142650A1 (en) * 2010-12-07 2012-06-07 John Hollingsworth Method for treating lung disease
US20120208767A1 (en) * 2011-02-14 2012-08-16 University Of Maryland, Baltimore Method to Detect or Treat Painful Bladder Syndrome based on Relation to Quinone Oxidoreductase 1
EP3498998A1 (en) * 2011-09-12 2019-06-19 Cummins Emission Solutions, Inc. Exhaust gas aftertreatment device
PT2768308T (pt) * 2011-10-14 2018-07-24 Univ Texas Compostos e substratos anti-tumorais nqo1
CN111481551B (zh) * 2013-04-09 2023-06-09 伊利诺伊大学董事会 肿瘤选择性联合疗法

Also Published As

Publication number Publication date
EP2984184A4 (en) 2016-11-30
CN111481551B (zh) 2023-06-09
MX2015014282A (es) 2016-07-20
JP2019163309A (ja) 2019-09-26
WO2014168991A1 (en) 2014-10-16
US10576096B2 (en) 2020-03-03
ES2853973T3 (es) 2021-09-20
PL2984184T3 (pl) 2021-06-14
HUE052930T2 (hu) 2021-05-28
AU2014251043B2 (en) 2020-01-16
BR112015025662A2 (pt) 2017-07-18
JP6719620B2 (ja) 2020-07-08
EP2984184A1 (en) 2016-02-17
US20160030457A1 (en) 2016-02-04
US10272099B2 (en) 2019-04-30
CA2909091A1 (en) 2014-10-16
CN111481551A (zh) 2020-08-04
US20180099002A1 (en) 2018-04-12
AU2020202453A1 (en) 2020-05-28
ZA201507755B (en) 2019-11-27
EP2984184B1 (en) 2020-11-25
AU2014251043A1 (en) 2015-11-05
DK2984184T3 (da) 2021-03-01
PT2984184T (pt) 2021-02-24
JP2016516775A (ja) 2016-06-09
CN105658809A (zh) 2016-06-08
AU2020202453B2 (en) 2022-04-14
CN105658809B (zh) 2020-03-27
MX2021000828A (es) 2021-03-25
JP6615746B2 (ja) 2019-12-04

Similar Documents

Publication Publication Date Title
AU2020202453B2 (en) Tumor-selective combination therapy
US10285986B2 (en) Compounds and anti-tumor NQO1 substrates
TW202128188A (zh) 抗癌化合物及其醫藥用途
WO2020205646A2 (en) Small molecule parg inhibitors and methods of use thereof
US20220098196A1 (en) Trapping-free parp inhibitors
WO2015077550A1 (en) Arylquinoline and analog compounds and use thereof to treat cancer
CA2501625A1 (en) X-nitro compounds, pharmaceutical compositions thereof and uses therof
Qi et al. Activatable near-infrared fluorogenic probe for monitoring GSH variations in synergistic PTX and RSL3 treatment of hypopharyngeal carcinoma
US20220160703A1 (en) Tumor-selective combination therapy
WO2022251654A1 (en) Mitoneet ligands for use in protection from tissue ischemic reperfusion injury

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181031

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251006

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260119

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260120